Anteneh M Feyissa1, Anna Carrano2, Xue Wang3, Mariet Allen3, Nilüfer Ertekin-Taner3, Dennis W Dickson4, Mark E Jentoft4, Steven S Rosenfeld5, William O Tatum3, Anthony L Ritaccio3, Hugo Guerrero-Cázares6, Alfredo Quiñones-Hinojosa7. 1. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Feyissa.Anteneh@mayo.edu. 2. Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. 3. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 4. Department of Pathology, Mayo Clinic, Jacksonville, FL, USA. 5. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; Department of Pharmacology, Mayo Clinic, Jacksonville, FL, USA. 6. Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Cazares.Hugo@mayo.edu. 7. Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Quinones-Hinojosa.Alfredo@mayo.edu.
Abstract
BACKGROUND: The pathogenesis of glioma-related seizures (GRS) is poorly understood. Here in, we aim to identify putative molecular pathways that lead to the development of GRS. METHODS: We determined brain transcriptome from intraoperative human brain tissue of patients with either GRS, glioma without seizures (non-GRS), or with idiopathic temporal lobe epilepsy (iTLE). We performed transcriptome-wide comparisons between disease groups tissue from non-epileptic controls (non-EC) to identify differentially-expressed genes (DEG). We compared DEGs to identify those that are specific or common to the groups. Through a gene ontology analysis, we identified molecular pathways enriched for genes with a Log-fold change ≥1.5 or ≤-1.5 and p-value <0.05 compared to non-EC. RESULTS: We identified 110 DEGs that are associated with GRS vs. non-GRS: 80 genes showed high and 30 low expression in GRS. There was significant overexpression of genes involved in cell-to-cell and glutamatergic signaling (CELF4, SLC17A7, and CAMK2A) and down-regulation of genes involved immune-trafficking (CXCL8, H19, and VEGFA). In the iTLE vs GRS analysis, there were 1098 DEGs: 786 genes were overexpressed and 312 genes were underexpressed in the GRS samples. There was significant enrichment for genes considered markers of oncogenesis (GSC, MYBL2, and TOP2A). Further, there was down-regulation of genes involved in the glutamatergic neurotransmission (vesicular glutamate transporter-2) in the GRS vs. iTLE samples. CONCLUSIONS: We identified a number of altered processes such as cell-to-cell signaling and interaction, inflammation-related, and glutamatergic neurotransmission in the pathogenesis of GRS. Our findings offer a new landscape of targets to further study in the fields of brain tumors and seizures.
BACKGROUND: The pathogenesis of glioma-related seizures (GRS) is poorly understood. Here in, we aim to identify putative molecular pathways that lead to the development of GRS. METHODS: We determined brain transcriptome from intraoperative human brain tissue of patients with either GRS, glioma without seizures (non-GRS), or with idiopathic temporal lobe epilepsy (iTLE). We performed transcriptome-wide comparisons between disease groups tissue from non-epileptic controls (non-EC) to identify differentially-expressed genes (DEG). We compared DEGs to identify those that are specific or common to the groups. Through a gene ontology analysis, we identified molecular pathways enriched for genes with a Log-fold change ≥1.5 or ≤-1.5 and p-value <0.05 compared to non-EC. RESULTS: We identified 110 DEGs that are associated with GRS vs. non-GRS: 80 genes showed high and 30 low expression in GRS. There was significant overexpression of genes involved in cell-to-cell and glutamatergic signaling (CELF4, SLC17A7, and CAMK2A) and down-regulation of genes involved immune-trafficking (CXCL8, H19, and VEGFA). In the iTLE vs GRS analysis, there were 1098 DEGs: 786 genes were overexpressed and 312 genes were underexpressed in the GRS samples. There was significant enrichment for genes considered markers of oncogenesis (GSC, MYBL2, and TOP2A). Further, there was down-regulation of genes involved in the glutamatergic neurotransmission (vesicular glutamate transporter-2) in the GRS vs. iTLE samples. CONCLUSIONS: We identified a number of altered processes such as cell-to-cell signaling and interaction, inflammation-related, and glutamatergic neurotransmission in the pathogenesis of GRS. Our findings offer a new landscape of targets to further study in the fields of brain tumors and seizures.
Authors: Joeri Van Liefferinge; Cathy J Jensen; Giulia Albertini; Eduard Bentea; Thomas Demuyser; Ellen Merckx; Eleonora Aronica; Ilse Smolders; Ann Massie Journal: Neurosci Lett Date: 2015-02-07 Impact factor: 3.046
Authors: W Saskia van der Hel; Suzanne A M W Verlinde; Dimphna H M Meijer; Marina de Wit; Marije G Rensen; Koen L I van Gassen; Peter C van Rijen; Cees W M van Veelen; Pierre N E de Graan Journal: Epilepsia Date: 2009-04-06 Impact factor: 5.864
Authors: Jason C You; Kavitha Muralidharan; Jin W Park; Iraklis Petrof; Mark S Pyfer; Brian F Corbett; John J LaFrancois; Yi Zheng; Xiaohong Zhang; Carrie A Mohila; Daniel Yoshor; Robert A Rissman; Eric J Nestler; Helen E Scharfman; Jeannie Chin Journal: Nat Med Date: 2017-10-16 Impact factor: 53.440
Authors: Humsa S Venkatesh; Wade Morishita; Anna C Geraghty; Dana Silverbush; Shawn M Gillespie; Marlene Arzt; Lydia T Tam; Cedric Espenel; Anitha Ponnuswami; Lijun Ni; Pamelyn J Woo; Kathryn R Taylor; Amit Agarwal; Aviv Regev; David Brang; Hannes Vogel; Shawn Hervey-Jumper; Dwight E Bergles; Mario L Suvà; Robert C Malenka; Michelle Monje Journal: Nature Date: 2019-09-18 Impact factor: 49.962
Authors: Giada Pauletto; Annacarmen Nilo; Christian Lettieri; Lorenzo Verriello; Barbara Tomasino; Gian Luigi Gigli; Miran Skrap; Tamara Ius Journal: Front Neurol Date: 2022-05-16 Impact factor: 4.086